BHP's Incoming CEO Visits China Amid Pricing Dispute with CMRG 
Alibaba Shares Slide as Jefferies Slashes Price Target Over AI Spending and Business Losses 
Goldman Sachs, ANZ Cut Oil Forecasts Amid U.S.-Iran Ceasefire Hopes 
Britain Courts Anthropic Amid US Defense Department Dispute 
Anthropic's Mythos AI Model Sparks Emergency Cybersecurity Meeting With Top U.S. Bank CEOs 
SpaceX IPO: Retail Investors to Play Historic Role in Record-Breaking Public Offering 
Paramount Skydance Secures $24B from Gulf Sovereign Wealth Funds for Warner Bros. Discovery Takeover 
China Vanke Seeks Bond Extension Amid Mounting Debt Crisis 
OpenAI Executive Shake-Up Ahead of Anticipated 2026 IPO 
Disney Plans to Cut 1,000 Jobs Amid Ongoing Restructuring Efforts 
Chalco Stock Surges as Q1 2025 Profit Forecast Jumps Up to 58% 
Samsung Electronics Eyes Record Q1 Profit Amid AI-Driven Chip Boom 
LG Electronics Posts Record Q1 Revenue Amid Strong Demand and Cost Improvements 
Foreign Investors Pour $18.65 Billion into Japanese Stocks Amid Market Stabilization 
Bendigo and Adelaide Bank Posts Strong Q3 Earnings, Announces AI-Driven Job Cuts 
UPS and Teamsters Reach Agreement to Limit Driver Severance Program 
FedEx Pilots and Union Reach Tentative Agreement on 40% Pay Increase 
COLUMBUS, Ohio, Aug. 30, 2016 -- Cleobrothers & Co., Inc. announced that it has recently opened a sales and marketing office in Salvador, Bahia, Brazil as part of its global expansion plan for promoting and distributing pharmaceuticals and hi-tech medical devices in South America, Asia, Africa and the Middle East.
|
|||||
A photo accompanying this announcement is available at http://www.globenewswire.com/NewsRoom/AttachmentNg/dcf12437-65fb-4d2f-a34d-6246da1f7ec6
According to Mr. Innocent Nweze, CEO of Cleobrothers and Co. Inc., “With a population exceeding 200 million people, Brazil provides tremendous potential for launching our brand of over-the-counter medications to retail and medical markets.”
The company currently has a portfolio of over-the-counter (OTC) cold relief and decongestant medications and over 80 Specialty Dermatology/Personal Skin Care Products that are specially formulated for tropical climates.
In addition, Cleobrothers offers a pipeline of two first-in-class technologies -- a 24/7 proprietary Pregnancy Monitoring device and a new Combination Pharmaceutical for management of Type-2 Diabetes. Both technologies are currently in clinical trials with product launches planned for the first quarter of 2017.
The new office will be located at Av. Tancredo Neves, 450-15° andar, 16th Floor, Caminho das Árvores Salvador, BA 41819-900, Brazil. Phone: +55 (71) 3340-0600.
“Having access to U.S. manufactured and FDA approved medications adds a strong competitive advantage to our sales and marketing efforts in Brazil,” Mr. Nweze added.
The Brazilian office opening comes on the heels of the company’s recent announcement of a joint venture agreement with PGC Solutions, Ltd. to distribute, market and promote Cleobrothers branded products in Nigeria.
Cleobrothers & Co., Inc. is a Columbus based biotechnology company focused on researching and developing medical and healthcare innovations that are dedicated to helping people worldwide live better lives.
For more information about Cleobrothers and Co., Inc. visit www.cleobrothers.com
(Office Photo attached)
Contact: Innocent Nweze email: [email protected] Phone: 614.934.1367
